Description: Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
Home Page: www.clearmindmedicine.com
CMND Technical Analysis
1220 West 6th Avenue
Vancouver,
BC
V6H 1A5
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Dr. Adi Zuloff-Shani Ph.D. | Chief Exec. Officer |
| Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA | CFO & Director |
| Prof. Mark Haden | VP of Bus. Devel. |
| Mr. Gilad Babchuk | Head of Strategy & Communication |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 27.7729 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-08-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |